[New progestins in oral hormonal contraceptives].
Three new progestins with a high gestagenic potency have been developed as derivatives of the levonorgestrel (in brackets: biological active substance in the human): desogestrel (3-keto-desogestrel), norgestimate (norgestimate), gestodene (gestodene). In combination with low dosages of ethinylestradiol (30-35 micrograms) an excessive steroid overload can be avoided, which is not necessary for contraceptive efficacy and control of the menstrual cycle. As an effect of dose reducing during long-time studies only a mild impact on the lipids and carbohydrates, and blood coagulation could be observed. The clinical side effects are moderate and for most patients acceptable.
Runnebaum
B
B
Abteilung für Gynäkologische Endokrinologie, Universitäts-Frauenklinik Heidelberg.
Rabe
T
T
D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D010060:Ovulation / Q000187:drug effects; D045167:Progesterone Congeners / Q000008:administration & dosage*; D013329:Structure-Activity Relationship
D003278:Contraceptives, Oral, Hormonal; D045167:Progesterone Congeners
Neue Gestagene in oralen hormonalen Kontrazeptiva.